Monday, April 15, 2013
Ltd. is using blood samples that have been taken annually by the U.K.
Collaborative Trial for Ovarian Cancer Screening to identify serum biomarkers
that can detect breast, lung, pancreatic and colorectal tumors at least one
year before symptomatic presentation.
Cancer biomarkers identified
through comparisons of samples from diagnosed cancer patients and matched
healthy controls may not be useful for widespread screening as they rely on threshold levels that
may miss cancer in individuals with biomarkers that are rising but low, or
falsely diagnose a healthy subject with naturally high levels.